23 August 2025

Howe Street Reporter Title

Category: Health Science

  • Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan

    Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan

    Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…

  • Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal

    Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal

    Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…

  • Bioasis Technologies (BTI.V) and the painful price of private sector science

    Bioasis Technologies (BTI.V) and the painful price of private sector science

    Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…

  • Perimeter Medical Imaging (PINK.V) successfully commercializes their breast cancer technology

    Perimeter Medical Imaging (PINK.V) successfully commercializes their breast cancer technology

    In the biotech/medtech world, the steps to viability as a company are proving your technology works, getting that technology approved by the FDA, finding doctors who are interested in using it, and commercializing the product so it can be manufactured to scale. Perimeter Medical Imaging (PINK.V) just made it through the final boss level. Perimeter…

  • Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making

    Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making

    The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If you were able to live to the age of 90 and retain either the mind or body of a 30-year-old for the last 60 years of…

  • Aequus Pharma (AQS.V) update including Q1,2021 financial highlights

    Aequus Pharma (AQS.V) update including Q1,2021 financial highlights

    On May 31, 2021 Aequus Pharmaceuticals (AQS.V) reported financial results for Q1, 2021. Aequus is a $19 million pharmaceutical company focused on developing and commercializing high quality, differentiated products. AQS is building a Canadian commercial platform through its own development pipeline and through license-acquisition. On November 20, 2020 Equity Guru’s Chris Parry spoke with Aequus’…

  • Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts

    Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts

    Anyone else watching charts trend downwards? Yeah. There’s a reason that junior market traders hold tight to the saying of “May: sell and go away”, but ‘May’ started unusually early this year. The biggest catalyst of course being the social upheaval that comes with different economies being at different stages of vaccination – and therefore…

  • Cybin (CYBN.E) new tryptamine patent improves outcome quality

    Cybin (CYBN.E) new tryptamine patent improves outcome quality

    Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…

  • Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech

    Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech

    Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to raise a considerable amount of cash while having its hands in several different buckets, bringing in $23 million CAD on a bought deal back in February. Mind…

  • XPhyto (XPHY.C) partner will begin sale of rapid Covid-ID Lab tests in Germany next week

    XPhyto (XPHY.C) partner will begin sale of rapid Covid-ID Lab tests in Germany next week

    XPhyto Therapeutics (XPHY.C) announced their partner Max Pharma GmbH will begin to sell XPhyto’s rapid point-of-care Covid-19 PCR test system (Covid-ID Lab) in Germany next week. The Covid-ID Lab test provides quality testing for the Covid-19 virus, achieving a 95% confidence interval, and delivering results within 25 minutes. Covid-ID Lab is registered within the European…